Compare Recursion Pharmaceuticals Inc (RXRX) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sezzle Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B), while Sezzle Inc trades at $125.74 (market cap $4.32B). The key difference: Sezzle Inc is far larger — about 2.4× Recursion Pharmaceuticals Inc's market cap, and Sezzle Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SEZL | |
|---|---|---|
Market Cap | $1.81B | $4.32B |
Sector | Health | Technology |
52-Week High | $6.79 | $188.55 |
52-Week Low | $2.84 | $50.97 |
Enterprise Value | $1.33B | $4.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Sezzle (SEZL) trades at $125.06, up 5.98% with strong recent earnings performance, beating estimates for three consecutive quarters. The stock shows bearish technical signals despite robust fundamentals including 72.36% gross margins and 30.35% net income margins. Recent Q2 2026 results showed 51.7% revenue growth to $149.7 million with raised full-year guidance, though the stock experienced significant volatility following the report.
The outlook remains positive with analyst consensus target of $158.29 representing 26.6% upside, though elevated valuation multiples and technical weakness present near-term headwinds. Execution on growth initiatives and margin maintenance will be critical for sustained appreciation amid competitive fintech landscape and market volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
